Regeneron (REGN): Taking On A Partner - Baird

September 21, 2016 8:28 AM EDT
Get Alerts REGN Hot Sheet
Price: $368.95 --0%

Rating Summary:
    19 Buy, 18 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 4
Trade REGN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Baird analyst, Brian Skorney, reiterated his Neutral rating on shares of Regeneron Pharma (NASDAQ: REGN) after Regeneron and Teva announced a collaboration deal for rights to fasinumab, Regneron's Phase 3 NGF antibody for chronic pain. The market for anti-NGF antibodies could be significant given the prevalence of chronic pain and osteoarthritis, but the mechanism has been plagued by safety concerns.

In return for a $250M upfront payment, Teva gains a 50% stake in the drug, worldwide (excluding other collaborations with Mitsubishi Tanabe in Asia), including rights to revenues and the obligation to pay what Regeneron estimates as about $1B in development costs. Both companies will share in commercialization costs, and Regeneron will be eligible to receive milestone payments along the way on development, regulatory, and sales-related events, worth up to almost $2.4B.

The potential market for osteoarthritis and chronic pain is estimated to be in the tens of millions of patients in the U.S. However, the anti-NGF mechanism has a troubled history and revenue from this product is likely not embedded in expectations.

No change to the price target of $448.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $406.24 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Robert W Baird

Add Your Comment